Tests irreversible electroporation for treating localized prostate cancer
Tests a device-based treatment, irreversible electroporation, in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Prostate Irreversible Electroporation Study
Key facts
- Where
- Hong Kong, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT06886321, who can take part
Where in Hong Kong
- Prince of Wales Hospital / The Chinese University of Hong KongHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT06886321
- Record updated
- 27 October 2026
- Original description
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. Among the different options of focal therapy, Irreversible electroporation has evolved over the past decades and can be a reliable treatment option. Our study aims at assess the safety and effectiveness of such treatment in prostate cancer management.Read full original descriptionShow less
Evaluation of the Effectiveness of Irreversible Electroporation for the Treatment of Prostate Cancer
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. Among the different options of focal therapy, Irreversible electroporation has evolved over the past decades and can be a reliable treatment option. Our study aims at assess the safety and effectiveness of such treatment in prostate cancer management.
Inclusion: Men aged between 40 - 85 years; Visible index lesion(s) on MRI; Found to have localized prostate cancer after MRI-USG fusion targeted biopsy or USG-guided template biopsy: Clinical tumour stage <=T2, or Gleason score <=7, or PSA <= 20 ng/ml.
Exclusion: Patients with active urinary tract infection; Patients with bladder pathology including bladder stone and bladder cancer; Patients unfit for contrast MRI exam; Patients with urethral stricture; Patients with neurogenic bladder and/or sphincter abnormalities; Patients who fail to give informed consent.